Mirum Pharmaceuticals, Inc.

MIRM

US6047491013

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-22 pm EST			5-day change	1st Jan Change
96.03 ^USD	+2.96%		+4.02%	+21.57%

Jan. 14	Mirum Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 11:15 AM
Jan. 14	Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2026	CI

Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics

Published on 12/08/2025 at 09:01 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Mirum Pharmaceuticals, Inc.

Jan. 14	Mirum Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 11:15 AM
Jan. 14	Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2026	CI
Jan. 12	Baird Adjusts Mirum Pharmaceuticals Price Target to $95 From $88, Maintains Outperform Rating	MT
Jan. 12	Mirum Pharmaceuticals 2025 Preliminary Revenue Rises; 2026 Outlook Set	MT
Jan. 12	Mirum Pharmaceuticals announces preliminary unaudited 2025 results, demonstrating strong commercial growth and pipeline momentum	RE
Dec. 30	XOMA Royalty Amends Takeda Deal, Expects Royalties Tied to Broader Asset Portfolio	MT
Dec. 30	XOMA Royalty Corporation Amends Its Collaboration with Takeda Through Strategic Royalty Share Transaction	CI
Dec. 19	Mirum Pharmaceuticals announces additional private placement financing with TCGX	RE
Dec. 19	Mirum Pharmaceuticals Agrees to $68.5 Million Equity Private Placement	MT
Dec. 17	Mirum Pharmaceuticals, Inc. announced that it expects to receive $68.48 million in funding from TCG Crossover Management, LLC	CI
Dec. 09	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Dec. 09	Sector Update: Health Care	MT
Dec. 09	Mirum Pharmaceuticals' Bluejay Acquisition Expands Liver Disease Pipeline, Morgan Stanley Says	MT
Dec. 09	Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $95 From $81, Keeps Overweight Rating	MT
Dec. 08	Bluejay Therapeutics, Inc., Mirum Pharmaceuticals, Inc. - M&A Call
Dec. 08	Mirum Pharmaceuticals, Inc. entered into a definitive agreement to acquire Bluejay Therapeutics, Inc for $810 million.	CI
Dec. 08	HBM Healthcare Investments Set to Receive Payments from Portfolio Company Sale	MT
Dec. 08	Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug	RE
Dec. 08	Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics	RE
Dec. 08	Mirum Pharmaceuticals enters into definitive agreement to acquire Bluejay Therapeutics	RE
Dec. 08	Mirum Pharma to buy Bluejay Therapeutics for up to $820 million	RE
Dec. 06	Mirum Pharmaceuticals, Inc. announced that it expects to receive $200.068444 million in funding	CI
Dec. 02	Mirum Pharmaceuticals Insider Sold Shares Worth $3,700,000, According to a Recent SEC Filing	MT
Dec. 02	Mirum Pharmaceuticals, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 02:10 PM
Dec. 01	Mirum Pharmaceuticals Says First Patient Enrolled in Phase 2 Fragile X Syndrome Therapy Trial of MRM-3379	MT

Chart Mirum Pharmaceuticals, Inc.

Duration

Period

MIRM: Dynamic Chart

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Employees

355

Sector

Pharmaceuticals

Calendar

Mar. 10 - Q4 2025 Earnings Release (Projected)

More about the company